Medtronic buys gel with sinus surgery prospects

February 25, 2011 by MedCity News

Medtronic acquires chitosan-dextran gel technology, which the company hopes will one day make endoscopic sinus treatments safer.

Medtronic logo

The world’s largest medical device maker bought the rights to a technology that it hopes can one day develop products for functional endoscopic sinus surgery.

Minneapolis-based Medtronic Inc. (NYSE:MDT) said that the so-called chitosan-dextran gel technology was acquired from Robinson Squidgel Ltd., the University of Adelaide in Australia and the University of Otago in New Zealand.

A Medtronic spokesman declined to provide the purchase price for the technology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.